Astrazeneca (AZN) Total Liabilities (2009 - 2026)

Astrazeneca has reported Total Liabilities for 18 years, with the latest figure at -$65.5 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 3.18% year-over-year to -$65.5 billion in Q2 2026; TTM through Jun 2026 was -$65.5 billion, a 3.18% increase from a year earlier, with the FY2025 full-year figure at -$65.4 billion, down 3.47% from the prior year.
• Total Liabilities was -$65.5 billion for Q2 2026 at Astrazeneca, up from -$66.6 billion in the prior quarter.
• The five-year high for Total Liabilities was -$58.9 billion in Q3 2023, with the low at -$68.5 billion in Q3 2025.
• Average Total Liabilities over 5 years is -$63.3 billion, with a median of -$64.0 billion recorded in 2022.
• The largest YoY upside for Total Liabilities was 12.3% in 2022 against a maximum downside of 26.61% in 2022.
• Over 5 years, Total Liabilities stood at -$59.4 billion in 2022, then retreated by 4.25% to -$62.0 billion in 2023, then slipped by 1.95% to -$63.2 billion in 2024, then declined by 3.47% to -$65.4 billion in 2025, then dropped by 0.17% to -$65.5 billion in 2026.
• The last three Total Liabilities figures came in at -$65.5 billion (Q2 2026), -$66.6 billion (Q1 2026), and -$65.4 billion (Q4 2025), per Business Quant data.